The Motley Fool
22 Nov 2026, 17:44 UTC · 24m ago
Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy for 2027?
Impact · against what's priced in
The article provides no catalyst for BMY or NVDA, as their listed metrics and price movements are already reflected in current valuations. For NVO, the high gross margins and low P/E ratio suggest a valuation dislocation, though these are general fundamental observations rather than new developments.
- BMY+0.00
Already priced in
- The price assumes
Current cash generation: $12.85bn free cash flow at a 26.7% margin supports a 7.7% free-cash-flow yield





